TN
Tango Therapeutics, Inc.
TNGX · NASDAQ
$22.33 +1.36% (+$0.30)
1M -8.89%
Market Cap $3.82B
P/E Ratio -
Div. Yield -
ROE 25.74%
Piotroski F-Score Weak
2/9Valuation
27 /100
Expensive P/B 3.73x
P/S 71.07x
EV/EBITDA N/A
Growth
97 /100
Growing Book val. growth 11.54%
Rev. growth 35.89%
FCF growth N/A
Profitability
20 /100
Weak Net margin 229.92%
Op. margin 253.38%
FCF margin 268.10%
Quality
1 /100
Poor ROE 25.74%
ROA 11.52%
Asset turnover 0.05x
Debt
100 /100
Low Current ratio 50.82x
Debt/Equity 0.03x
Net debt/EBITDA N/A
Stability
64 /100
Moderate Rev. volatility 18.74%
EPS volatility 18.67%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TNGX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Malte Peters
Employees
137
Headquarters
Boston
Upcoming events
03 NOV
Earnings
Upcoming earnings report